Transcripts Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 24/08/2026 BST			5-day change	1st Jan Change
13.78 ^USD	-3.67%		-11.13%	-12.15%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

15/01/25	Monte Rosa Therapeutics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 05:15 PM
17/10/23	Monte Rosa Therapeutics, Inc. - Special Call

No results match your criteria